Scandion Oncology A/S: Financial statements 2018
CVR: 38613391
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Scandion Oncology A/S (CVR 38613391) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -7,385,008 and a net result of DKK -8,182,558. Equity in the 2018 report amounted to DKK 12,570,107. The solvency ratio was 92.7%. The company had 2 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -7,385,008
- Profit/Loss
- DKK -8,182,558
- Equity
- DKK 12,570,107
- Total Assets
- DKK 13,562,750
- Employees
- 2
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of July 5, 2018, Nils Aage Brünner is registered as adm. dir. of Scandion Oncology A/S.
As of July 5, 2018, Jørgen Vilhelm Løvenørn Bardenfleth is registered as chairman of Scandion Oncology A/S.
As of July 5, 2018, Thomas Feldthus is registered as vice chairman of Scandion Oncology A/S.
As of July 5, 2018, Kim Arvid Nielsen has stepped down as adm. dir. of Scandion Oncology A/S.
As of July 5, 2018, Nils Aage Brünner has stepped down as chairman of Scandion Oncology A/S.
As of July 4, 2018, Jørgen Vilhelm Løvenørn Bardenfleth has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its interim report for the period May 2, 2017 to December 31, 2017.
About Scandion Oncology A/S
Scandion Oncology A/S was a Danish company of the type Aktieselskab based in København Ø, founded in 2017. The company has been dissolved on 6 October 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -6,100,000 and a net result of DKK -8,286,000. Equity in the 2025 report amounted to DKK 0.
